FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034771291> ?p ?o ?g. }

• W3034771291 endingPage "302" @default.
• W3034771291 startingPage "301.1" @default.
• W3034771291 abstract "Background: Cervical lesions are known to occur at high frequency as a complication of rheumatoid arthritis (RA). Treatment with biological agents are more clinically effective than the DMARDs that were in use previously, in particular, with their efficacy in suppressing joint destruction having been emphasized. We reported the efficacy of infliximab, anti-tumor necrosis factor antibodies for suppressing the radiographic progression of RA cervical lesions at ACR2009, EULAR2010, 11, 12, 13, 14,16 and 18. However there is still few studies of efficacy of against RA cervical lesions of Abatacept (ABT) that inhibits T cell activation by binding to CD80/86. Objectives: To evaluate the efficacy of ABT for suppressing the radiographic progression of RA cervical lesions comparison with MTX for 2 years. Methods: We used ABT or MTX for treating Japanese patients with active RA who fulfilled the ACR criteria in 1987. The final study cohort of each 60 and 75 patients received continuous ABT and MTX treatment for at least 2 years. For evaluation of cervical lesions, the atlanto-dental interval (ADI), the space available for the spinal cord (SAC), and the Ranawat value were measured by plain lateral radiographs in the flexion position, at initiation and Year 1,2. Results: In the patients receiving ABT (n=60) and MTX (n =75), the number of female were each 48(80%) and 52(69%) cases(p=0.160). The mean age was 67.7 ± 12.9 and 63.6 ± 11.0 years old (p=0.004); disease duration was 16.7 ± 14.2 and 8.0 ± 9.5 years (p<0.001) and the mean dose of MTX was 8.4 ± 3.6 and 8.2 ± 2.9 mg/w (p=0.804). Clinical findings related to RA were as follows; CRP 2.2± 2.1 and 1.7± 2.3 mg/dl(p=0.008); ESR 47.2 ± 23.4 and 31.9 ± 21.8mm/h(p<0.001); MMP3 253 ± 280 and 223 ± 350ng/ml(p=0.003); the number of RF-positive 57(95%) and 60(80%) cases(p=0.011); DAS28-ESR 5.13 ± 0.99 and 4.30 ± 1.38 (p<0.001); ADI 3.6 ± 2.1 and 2.6 ± 1.6mm(p=0.003); SAC 18.5 ± 2.8 and 20.8 ± 2.5mm(p<0.001) and Ranawat value 14.4 ± 1.9 and 16.0 ± 1.5mm (p<0.001). The respective changes in cervical lesion parameters after 1 year were as follows: ADI: 0.20 ± 0.40 and 0.27 ± 0.45 mm (p = 0.367); SAC: −0.12 ± 0.32 and −0.17 ± 0.38 mm (p = 0.359); and Ranawat value: −0.15 ± 0.36 and −0.13 ± 0.34 mm (p = 0.783). The respective changes in cervical lesion parameters after 2 years were as follows: ADI: 0.35 ± 0.58 and 0.55 ± 0.70 mm (p = 0.099); SAC: −0.25 ± 0.47 and −0.45 ± 0.62 mm (p = 0.047); and Ranawat value: −0.23 ± 0.47 and −0.33 ± 0.55 mm (p = 0.293) in the patients receiving ABT and MTX (Fig. 1). The numbers of patients who did not showed progression in ADI, SAC and Ranawat value were each 42(70%) and 43(57%) cases(p=0.130); 46(77%) and 46(61%) cases(p=0.057) and 47(78%) and 53(71%) cases(p=0.313) after 2 years. Also the number who was able to suppress progression in all three parameters were each 42 cases (70%) receiving ABT and 43 cases (57%) receiving MTX (p=0.130) after 2 years (Fig. 2). Conclusion: This study suggested that ABT treatment can be used to suppress the progression of RA cervical lesions more than MTX treatment. Disclosure of Interests: Yasuhide Kanayama: None declared, Toshihisa Kojima Grant/research support from: Chugai, Eli Lilly, Astellas, Abbvie, and Novartis, Consultant of: AbbVie, Speakers bureau: AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eli Lilly, Janssen, Mitsubishi Tanabe, Pfizer, and Takeda, Yuji Hirano Speakers bureau: Tanabe-Mitsubishi, Pfizer, Eisai, Abbie, Chugai, Bristol-Meyers, Jansen, Astellas, UCB, Eli-Lilly, Asahikasei, Daiichi-Sankyo, Amgen, Nobunori Takahashi Speakers bureau: AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Mitsubishi Tanabe, Ono, Pfizer, Takeda, and UCB Japan, Yukiyoshi Oishi: None declared, Naoki Ishiguro Grant/research support from: AbbVie, Asahi Kasei, Astellas, Chugai, Daiichi-Sankyo, Eisai, Kaken, Mitsubishi Tanabe, Otsuka, Pfizer, Takeda, and Zimmer Biomet, Consultant of: Ono, Speakers bureau: Astellas, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Pfizer, and Taisho Toyama" @default.
• W3034771291 created "2020-06-19" @default.
• W3034771291 creator A5004086646 @default.
• W3034771291 creator A5017609785 @default.
• W3034771291 creator A5059137955 @default.
• W3034771291 creator A5077922260 @default.
• W3034771291 creator A5086204817 @default.
• W3034771291 creator A5089659933 @default.
• W3034771291 date "2020-06-01" @default.
• W3034771291 modified "2023-09-28" @default.
• W3034771291 title "THU0171 EFFICACY OF ABATACEPT FOR SUPPRESSING RADIOGRAPHIC PROGRESSION OF CERVICAL LESIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARISON WITH METHOTREXATE TREATMENT; TWO YEARS OF FOLLOW-UP ~A MULTICENTER REGISTRY STUDY ~" @default.
• W3034771291 doi "https://doi.org/10.1136/annrheumdis-2020-eular.4272" @default.
• W3034771291 hasPublicationYear "2020" @default.
• W3034771291 type Work @default.
• W3034771291 sameAs 3034771291 @default.
• W3034771291 citedByCount "0" @default.
• W3034771291 crossrefType "journal-article" @default.
• W3034771291 hasAuthorship W3034771291A5004086646 @default.
• W3034771291 hasAuthorship W3034771291A5017609785 @default.
• W3034771291 hasAuthorship W3034771291A5059137955 @default.
• W3034771291 hasAuthorship W3034771291A5077922260 @default.
• W3034771291 hasAuthorship W3034771291A5086204817 @default.
• W3034771291 hasAuthorship W3034771291A5089659933 @default.
• W3034771291 hasConcept C126322002 @default.
• W3034771291 hasConcept C141071460 @default.
• W3034771291 hasConcept C17991360 @default.
• W3034771291 hasConcept C2777138892 @default.
• W3034771291 hasConcept C2777575956 @default.
• W3034771291 hasConcept C2779338263 @default.
• W3034771291 hasConcept C2779605438 @default.
• W3034771291 hasConcept C2780653079 @default.
• W3034771291 hasConcept C2781059491 @default.
• W3034771291 hasConcept C71924100 @default.
• W3034771291 hasConcept C90924648 @default.
• W3034771291 hasConceptScore W3034771291C126322002 @default.
• W3034771291 hasConceptScore W3034771291C141071460 @default.
• W3034771291 hasConceptScore W3034771291C17991360 @default.
• W3034771291 hasConceptScore W3034771291C2777138892 @default.
• W3034771291 hasConceptScore W3034771291C2777575956 @default.
• W3034771291 hasConceptScore W3034771291C2779338263 @default.
• W3034771291 hasConceptScore W3034771291C2779605438 @default.
• W3034771291 hasConceptScore W3034771291C2780653079 @default.
• W3034771291 hasConceptScore W3034771291C2781059491 @default.
• W3034771291 hasConceptScore W3034771291C71924100 @default.
• W3034771291 hasConceptScore W3034771291C90924648 @default.
• W3034771291 hasIssue "Suppl 1" @default.
• W3034771291 hasLocation W30347712911 @default.
• W3034771291 hasOpenAccess W3034771291 @default.
• W3034771291 hasPrimaryLocation W30347712911 @default.
• W3034771291 hasRelatedWork W1981566289 @default.
• W3034771291 hasRelatedWork W2002255156 @default.
• W3034771291 hasRelatedWork W2014382789 @default.
• W3034771291 hasRelatedWork W2039301982 @default.
• W3034771291 hasRelatedWork W2047008351 @default.
• W3034771291 hasRelatedWork W2319957449 @default.
• W3034771291 hasRelatedWork W2914834251 @default.
• W3034771291 hasRelatedWork W2987008883 @default.
• W3034771291 hasRelatedWork W3048731972 @default.
• W3034771291 hasRelatedWork W2786604379 @default.
• W3034771291 hasVolume "79" @default.
• W3034771291 isParatext "false" @default.
• W3034771291 isRetracted "false" @default.
• W3034771291 magId "3034771291" @default.
• W3034771291 workType "article" @default.